HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer.

ABSTRACT: The lethality of estrogen receptor alpha positive (ER+) breast cancer, which is often considered to have better prognosis than other subtypes, is defined by resistance to the standard of care endocrine treatment. Relapse and metastasis are inevitable in almost every patient whose cancer is resistant to endocrine treatment. Therefore, understanding the underlying causes of treatment resistance remains an important biological and clinical focus of research in this area. Growth factor receptor pathway activation, specifically HER2 activation, has been identified as 1 mechanism of endocrine treatment resistance across a range of experimental model systems. However, clinical trials conducted to test whether targeting HER2 benefits patients with endocrine treatment-resistant ER+ breast cancer ha

SUBMITTER: Mazumder A 

PROVIDER: S-EPMC8379900 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature